Pharmaceuticals company Sai Life Science announced Q2FY26 results Revenue from Operations was Rs 537 crore for Q2FY26 compared to Rs 396 crore in Q2FY25, an increase of 36% driven by strong growth both in CRO and CDMO services. EBITDA stood at Rs 156 crore for Q2FY26 compared to Rs 109 crore in Q2FY25, an increase of 43%. PAT stood at Rs 84 crore for Q2FY26 compared to Rs 42 crore in Q2FY25, an increase of 100% Krishna Kanumuri, Managing Director & CEO, Sai Life Sciences, said: “We are pleased to report another strong quarter, supported by healthy demand across our discovery, development, and manufacturing services. The performance was driven by consistent execution, growing client relationships, and continued traction in late-stage and commercial programs. As the industry evolves toward more complex and diversified science, we continue to invest in new modalities, advanced technologies, and capacity expansion to strengthen our long-term competitiveness. These investments are enabling us to address a broader range of client needs, enhance efficiency across the value chain, and build deeper scientific capabilities for the future. Looking ahead, our priorities remain centered on scaling responsibly, advancing technology-led innovation, and deepening client collaborations. With a strong foundation, expanding infrastructure, and scientific excellence at the core of our strategy, Sai Life Sciences is well positioned to deliver sustainable growth and long-term value." Siva Chittor, Whole-time Director & Chief Financial Officer, Sai Life Sciences, said: “We sustained our positive momentum this quarter, maintaining growth across our business and keeping Sai Life Sciences firmly on track toward its long-term aspirations. Total revenue for Q2FY26 stood at Rs 537 crore, up 36% year-on-year, driven by healthy performance across both the CRO and CDMO services. EBITDA for the quarter was Rs 156 crore, with margins at 29%, supported by improved operating leverage, better utilization and continued cost discipline. We incurred capex of Rs 248 crore during H1, primarily directed toward expanding our R&D; capacity, and advancing our offerings in new modalities and technologies. These investments are aligned with our strategy to enhance scientific depth and build scalable capacity to support future growth. We remain focused on maintaining financial discipline, driving margin improvement, and deploying capital effectively to sustain long-term, profitable growth.” Result PDF